80 results about "Drugs stability" patented technology

The invention relates to a layered drug-loading microneedle patch as well as a preparation method and application thereof. The preparation method of the layered drug-loading microneedle patch comprises the following steps: S1, dissolving a drug and a soluble high-molecular polymer in a solvent according to a mass ratio of (2: 1)-(1: 12) to form a needle tip solution, then filling a needle tip cavity of a microneedle mold with the needle tip solution, drying, and removing redundant drug residues on the surface to form a drug-loading needle tip layer; and S2, filling a mold containing the drug-loading needle tip layer with a photocurable polymer, performing ultraviolet curing for 10-30 seconds under the wavelength of 365-405 nm, and then performing demolding to form a substrate layer, thereby obtaining the layered drug-loading microneedle patch. According to the method, one-time filling of the needle tip part is successfully achieved by combining needle tip auxiliary material proportion optimization, meanwhile, the curing process is rapid, the medicine utilization rate and the process stability are remarkably improved, the medicine stability is good, and the method is suitable for industrial production.

The invention relates to the field of drug stability evaluation, in particular to an anti-generative drug stability evaluation system and method. Comprising a confrontation sample simulation module, a drug stability test module and an intelligent identification module. The system generates an anti-noise, self-adaptive and stable adversarial sample based on a drug molecular structure, and predicts drug stability under different conditions through environmental physical simulation and a digital twinborn model. And the intelligent identification module executes molecular fragment sensitivity analysis, predicts stability under extreme conditions and outputs an evaluation report. The system solves the problems of efficiency, precision and application range in the prior art, realizes qualitative change evaluation through innovative technology combination, provides a scientific basis for drug research and development, transportation and storage, and remarkably improves the drug stability evaluation level.

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a compound I patch composition, a compound I patch and a preparation method thereof. The patch composition comprises the following components in parts by weight: 0.5-12 parts of a pharmaceutical active component, 10-30 parts of a penetration enhancer, 15-56 parts of a crystal inhibitor and 35-57 parts of an acrylic acid pressure-sensitive adhesive, the patch composition also comprises solvent dimethyl sulfoxide and absolute ethyl alcohol, and the residual quantity of the dimethyl sulfoxide is not less than 2.0%; wherein the active pharmaceutical ingredient is a compound I, and the structural formula of the compound I is shown in the specification. According to the patch composition containing the compound I, the medicine stability is high, medicine crystallization and impurity generation are effectively avoided or reduced, and the patch containing the compound I has higher stability and safety; the patch composition containing the compound I has more appropriate drug permeability, so that the patch containing the compound I has higher drug effectiveness.

The invention discloses a gelatinized and / or micronized nucleoside drug and a preparation method thereof, and belongs to the technical field of drugs. The preparation method comprises the following steps: mixing lipoic acid, a nucleoside drug and an esterification catalyst, carrying out a grafting reaction in a reaction solvent to obtain a lipoic acid grafted nucleoside drug, dispersing the lipoic acid grafted nucleoside drug in an organic solvent to obtain a dispersion liquid, dropwise adding the dispersion liquid into hot water, and carrying out ring opening polymerization to obtain the lipoic acid grafted nucleoside drug. The nucleoside drug nanogel, nanoparticle or nanofiber is obtained, and the structure and performance improvement based on the drug itself is realized. The gelated and / or micronized nucleoside medicine prepared by the invention has obviously improved scavenging rates of DPPH free radicals and ABTS free radicals, and the method can improve the oxidation resistance of the nucleoside medicine and has the characteristic of improving the stability and functionality of the medicine.

The invention provides a nanocrystalline composite oral ulcer film agent as well as a preparation method and application thereof. The nanocrystalline composite oral ulcer film agent comprises a waterproof backing layer and a drug-loading adhesion layer coated on the waterproof backing layer, the drug-loaded adhesion layer comprises a macromolecular hydrogen bond compound formed by a weakly acidic polymer and a nonionic proton receptor polymer, and a nanocrystalline drug. Compared with the prior art, the preparation method has the advantages that the polyacrylic acid polymer and the nonionic cellulose polymer interact to form IPC serving as an adhesion layer film-forming material, the nanocrystals are loaded into the adhesion layer film-forming material, the waterproof backing layer is coated with the adhesion layer film-forming material, and the oral ulcer film agent is prepared after drying and cutting. The obtained film agent has good comfort and adhesive power, shows good drug stability and permeation promotion performance, can be used as a carrier of an oral administration route, prolongs the drug action time and improves the curative effect. The preparation method of the film agent is simple and easy for industrial mass production.

The invention discloses a preparation method of olmacycline tosylate for injection, belongs to the technical field of pharmaceutical preparations, and provides a special preparation and a preparation method of the olmacycline tosylate for injection in order to solve the problems that the olmacycline tosylate for injection is prone to epimerization and oxidative degradation and the room temperature stabilization time is short after redissolution. According to the preparation, omagazines tosylate is used as a main component and matched with glycerol, vitamin C, thioglycerol, sodium acetate and water for injection, and the pH is adjusted to a proper range through hydrochloric acid or sodium hydroxide. According to the method, by means of the synergistic effect of glycerin and vitamin C, glycerin fixes medicine molecules and protects vitamin C, vitamin C removes oxidation inducements, and thioglycerin is matched to assist in inhibiting degradation, so that the medicine stability is greatly improved, the redissolved liquid medicine can be stabilized at 25 DEG C for 72 hours, the total impurities are controlled at a low level, and the clinical actual requirements are met.

The present invention relates to a composition of aliphatic emulsion preparation for malignant thoracicoabdominal hydrops and its preparation method. It is made up by adopting pure natural anticancer medicine elemene and at least one polysaccharide selected from ginseng polysaccharide, astragalus polysaccharide, acanthopanax polysaccharide and lyceum polysaccharide as raw material. Said invention can obviously raise solubility of medicine, increase stability of medicine, effectively remove and kill cancer cells and raise immunity of body.

This invention arrests the hydrophilic silicone macrochains into semi-interpenetrating polymer network via in situ photo-gelation assisted 3D microextrusion printing technique. The printed hybrid hydrogel has shown microporous morphology with tunable diffusion behaviour. The flow behaviour of the hydrogel has been tested showing high elastic modulus, low tan δ, high gel strength, and delayed network rupturing behaviour. The uniaxial compression test showed the almost zero permanent set which could promote it as an elastomer mimetic soft biomaterial. Moreover, the drug loading into the hydrogel has been performed which showed hydrophilic silicone dependent non-Fickian anomalous transport. The encapsulated drug stability inside hydrogel matrices also showed no deterioration of the pristine drug molecules even after one month storage. This could be the first hydrodrophilic silicone based soft biomaterial will serve as an excellent controlled drug delivery device.

The invention belongs to the technical field of medicine manufacturing, and particularly relates to a compound preparation containing faropenem sodium as well as a preparation method and application of the compound preparation. According to the invention, the production prescription is optimized, the stability of the medicine can be effectively improved, the unpleasant smell of the medicine is covered, and the medication compliance of children is obviously improved. The epigallocatechin-aluminum complex can serve as a free radical scavenger in a preparation system, oxygen free radicals are effectively captured and neutralized, and the influence of oxidative stress on the medicine is reduced; moreover, the existence of aluminum ions not only enhances the stability of EGCG, but also reduces the drug degradation reaction under the catalysis of the ions through chelation with trace metal ions (such as iron, copper and the like) in the preparation. In addition, aluminum ions can also directly form a stable complex with faropenem sodium, so that the chemical stability of the faropenem sodium is further improved.

This application belongs to the field of biomedicine, specifically relating to a method for preparing an antitumor composition for pets, aiming to solve the technical problems of low bioavailability, poor stability, and poor drug administration compliance of poorly soluble active ingredients in antitumor drugs for pets. The method includes: a raw material pretreatment step, in which curcumin, resveratrol, quercetin, green tea polyphenols, and astragalus polysaccharides are pulverized and sieved separately; an organic phase preparation step, in which egg yolk lecithin and solid lipids are dissolved in an ethanol-acetone mixed solvent, and curcumin and resveratrol are added and dissolved by stirring in a water bath; an aqueous phase preparation step, in which poloxamer F68 is dissolved in purified water and dissolved in a water bath; a high-pressure homogenization step, in which a nanoemulsion containing a solid lipid core is prepared; a moderately polar component encapsulation step, in which quercetin and green tea polyphenols are ultrasonically dispersed and then added dropwise to the nanoemulsion; a freeze-drying step, in which a nano-lyophilized powder is obtained; and an outer hydrophilic component coating step, in which astragalus polysaccharides are sprayed or adsorbed onto the surface of the freeze-dried powder. The composition obtained by this method is a core-shell multilayer nanoparticle with a core consisting of curcumin and resveratrol encapsulated by solid lipids, a middle shell adsorbing quercetin and green tea polyphenols, and an outer shell coated with astragalus polysaccharides. This application utilizes the above-mentioned layered encapsulation technology to achieve stable co-encapsulation of multiple antitumor active ingredients, improve the bioavailability of poorly soluble components, optimize drug stability, and enhance antitumor effects through multi-target synergistic effects. Simultaneously, it endows the composition with immunomodulatory functions and sustained-release properties. The composition can be formulated into a nano-lyophilized powder form, making it easy to add to pet food or formulate into a paste for administration, improving pet drug compliance. Figure 2 is a schematic diagram of the three-layer core-shell nanoparticle structure of the composition of this invention.

The invention relates to process development of a preparation prescription of a coronavirus 3CL protease inhibitor compound Iscartrevir and a preparation method of the coronavirus 3CL protease inhibitor compound Iscartrevir. By strictly screening and optimizing the formula, the preparation with a specific prescription ratio is obtained. According to the preparation, the medicine stability is improved, through the overall synergistic effect of the dry granulation step, in the preparation process of the medicine components, the flowing property of totally mixed materials is good, and the sticking problem is further solved. Meanwhile, the preparation is simple in production process, short in production period, energy-saving, efficient, low in cost and suitable for industrial mass production.

The present application relates to the microRNA drug technical field, specifically to the application of hsa-let-7f-5p in the preparation of a drug for treating muscle steatosis, and discloses that hsa-let-7f-5p can inhibit muscle fat infiltration by inhibiting fibroblast / adipogenic progenitor cell adipogenic differentiation, and hsa-let-7f-5p can be used as a microRNA drug in the treatment of diseases such as muscle fat infiltration and muscle steatosis, and diseases related to fat infiltration, for example, muscle atrophy, muscle injury, obesity, diabetes, etc. The relevant nucleic acid fragments are wrapped in liposomes, so that the drug stability and drug efficiency can be improved. The technical scheme can solve the technical problem that there is no drug capable of effectively inhibiting muscle steatosis and treating muscle injury in the prior art, and has an ideal application and promotion prospect in the fields of sports medicine and rehabilitation treatment.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

This invention provides a nasal spray pharmaceutical composition containing CNI 3176, the composition comprising: a therapeutically effective amount of CNI 3176, or a pharmaceutically acceptable salt of CNI 3176, or a mixture of CNI 3176 and a pharmaceutically acceptable salt of CNI 3176. It may also contain pharmaceutically acceptable excipients, such as pharmaceutically used solvents, surfactants, and stabilizers. The composition of this invention contains surfactants and stabilizers, which can improve drug bioavailability and increase drug stability, without requiring control of raw material particle size.

The invention provides a rucotinib phosphate nanostructure lipid carrier, a preparation method and application thereof, and a rucotinib phosphate composition, and belongs to the technical field of pharmaceutical preparations. According to the rucotinib phosphate nanostructure lipid carrier and the rucotinib phosphate composition provided by the invention, the solid lipid and the liquid lipid are compounded, and the anti-crystallization agent is introduced, so that the rucotinib phosphate is encapsulated in the nanostructure lipid carrier core formed by the solid lipid and the liquid lipid; the problem of unique crystallization caused by a pyrazole structure of rucotinib phosphate is solved, and the compound has the advantages of high encapsulation efficiency and good stability. According to the invention, the rucotinib phosphate nanostructure lipid carrier is uniformly dispersed in a dermatologically acceptable matrix to obtain a composition containing a therapeutically effective amount of rucotinib phosphate, and the composition shows significantly enhanced drug stability and skin retention ability, and reduces the risk of system exposure.

The application provides a kind of antibiotic-loaded nanoemulsion and its preparation method and application, it is related to the technical field of medical adjuvant, antibiotic is mixed with medicinal adjuvant soybean oil, dipalmitoyl phosphatidylcholine and cholesterol, and volatile organic solvent is used to dissolve and form oil phase;Deoxycholic acid sodium and tween are dissolved in sterile liquid to form water phase;Oil phase and water phase are mixed, and are treated by ultrasonic treatment, rotary evaporation treatment and high pressure homogenization treatment, to obtain antibiotic-loaded nanoemulsion.The application adjusts the type of inhalable medicinal adjuvant, the addition ratio of inhalable medicinal adjuvant, the ratio of oil phase and water phase, and the ultrasonic power and homogenization pressure and other factors, so that the prepared nanoemulsion can efficiently load antibiotic, and has good aerosol inhalation performance, better drug stability, the nanoemulsion can be retained in mouse lung tissue for a long time, and the lung drug delivery efficiency is significantly improved.

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.

The application discloses a drug stability prediction method and system based on artificial intelligence, and relates to the technical field of drug discovery.The method comprises the following steps: obtaining sequence information of non-redundant proteins, constructing a protein large language model, training the protein large language model by using the sequence information of the non-redundant proteins, fine-tuning model parameters, and predicting polypeptide stability by using the protein large language model and physicochemical properties of the polypeptide.The application realizes stability prediction of a new polypeptide, outputs half-life regression and potential enzymolysis sites of the polypeptide, and provides guidance for amino acid site modification.Compared with existing models, the model has low training cost and low calculation complexity.In addition, in the fine-tuning of the adaptive task, the application only needs to adjust a small amount of parameters, so that the model training time is reduced, and catastrophic forgetting caused by fine-tuning is avoided.

The utility model relates to medicine test technical field, concretely is the temperature control constant humidity box of medicine stability test, including support base, the support base upper surface right -hand side fixed mounting has control mechanism, control mechanism left side installation has test box, the test box includes box, the hinge in box front side surface left end's door, fixed mounting in the middle position of box outside upper surface's motor and rotationally connected in the middle position of box inside's rotating shaft, the rotating shaft outer surface welds have a plurality of test carousel, each the test carousel is placed with a plurality of medicine placing mechanism on every. The utility model discloses through the setting of the rotating disc, makes the medicine in the constant temperature and humidity box when receiving test, can through the rotation and make the test personnel can observe the stability state of all medicines inside, place the medicine in the medicine placing mechanism inside, makes the medicine when the test carousel rotates, the medicine does not roll everywhere, is convenient for the observation of medicine.

The invention discloses a drug stability analysis system, which relates to the technical field of drug analysis and comprises a sample data acquisition module, a data fusion and regulation module, an intelligent analysis and state judgment module and a result output and trend prediction module, through comprehensive application of the optical imaging technology, the fluorescence imaging technology and the infrared imaging technology, multi-dimensional and all-directional scanning of a drug sample in the stability testing period is achieved, the comprehensiveness and accuracy of data acquisition are remarkably improved, the optical imaging technology captures macroscopic surface morphology information of a drug, and the stability of the drug sample is improved. The fluorescence imaging technology is used for carrying out visual tracking on specific components in the medicine to obtain component distribution information, and the infrared imaging technology is used for analyzing chemical bond vibration conditions among medicine molecules to obtain chemical composition information, so that materials are provided for subsequent data analysis and processing.

According to the nicking tablet containing nebivolol hydrochloride, silicified microcrystalline cellulose is used as a medicine excipient, the ratio of silicified microcrystalline cellulose to lactose is controlled, and a simple powder direct-pressing tabletting mode is adopted, so that the defect that when microcrystalline cellulose is used as the medicine excipient at present, the preparation process is complicated is overcome; the prepared tablets generally have the problems of high water content, poorer flowability and compressibility, slower dissolution rate, incomplete dissolution, poorer drug stability, more complicated preparation method and the like. The tablet prepared by the method has the advantages of extremely low water content, good content uniformity, better flowability and compressibility, higher dissolution rate and better stability, and the whole preparation method is simple and suitable for large-scale industrial production.

The invention discloses a pharmaceutical composition and a nano preparation, a preparation method and application thereof, and relates to the technical field of biomedicine.The pharmaceutical composition comprises gallium salt and levofloxacin, the molar ratio of the gallium salt to the levofloxacin is 4: 1-300: 1, and the nano preparation comprises a polyphenol compound and the pharmaceutical composition. The gallium salt and the polyphenol compound are coordinated and complexed to form a network structure, and levofloxacin is loaded; the preparation method is a fractional step method or a one-pot synthesis method. The medicine for treating pseudomonas aeruginosa infection, which is prepared from the nano preparation, is delivered to the lung in an atomization administration manner; the invention has the following beneficial effects: the synergistic antibacterial activity is significantly enhanced; the drug stability and bioavailability are improved; and a stable platform is provided for subsequent surface targeted modification.

The application discloses a teramycin ketoprofen injection and a preparation method thereof, and belongs to the field of veterinary injections, and is characterized by the following formula components: teramycin, ketoprofen, a catalytic factor, an antioxidant and an injection solvent; the catalytic factor is a polyamide amine dendrimer; and the antioxidant is a mixture of one or more than two of thio-glycerol, sodium metabisulfite or sodium bisulfite. The application has the beneficial effects that the teramycin and the ketoprofen are used in combination, no pH regulator is needed after the polyamide amine dendrimer is added, and an aqueous injection is obtained by the combination of the two, has a rapid effect, is rapidly absorbed after administration, has a short action time, can play a synergistic role in sterilization and inflammation, can not only increase the curative effect of a single drug, but also improve the drug stability and the bioavailability.

A dexamethasone sodium phosphate lyophilized composition suitable for administration to the eardrum and a preparation method therefor are provided. Provided is a lyophilized powder injection preparation, wherein the preparation is a dexamethasone medicament lyophilized powder injection omitting a lyophilization supporting agent or an excipient or a matrix agent, wherein the lyophilized powder injection preparation comprises pharmaceutically acceptable auxiliary material of glycerol, and the glycerol is added before the lyophilized powder injection preparation is lyophilized. The provided lyophilized preparation omits a lyophilized supporting agent or an excipient, achieving the effect of improving the stability of the drug by only adding a small amount of glycerol, and also allowing adjustment the osmotic pressure to be closer to the physiological osmotic pressure during the tympanogram administration and prolong the action time of local administration, thereby increasing the safety and effectiveness of the tympanogram administration.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention discloses an alfentanil micro-dose injection based on clinical precise administration and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the injection is packaged by adopting a single-use small-capacity polypropylene (PP) material ampoule or a pre-filled syringe, the single package capacity is 0.5-2mL, the alfentanil micro-dose injection contains 0.1-50mu g / mL of alfentanil, and the injection is prepared by adopting a one-time injection method. The PP material has good high-temperature sterilization resistance and low drug adsorbability, so that the terminal sterilization requirement can be met, the drug stability can be ensured, and meanwhile, the risk of disengagement possibly caused by glass packaging is avoided; and finally, through an optimized packaging design and a preparation process, a simplified formula without preservatives and solubilizers is realized, and potential safety hazards possibly brought by auxiliary materials are reduced. According to the scheme, a safer and more economical accurate administration solution of the alfentanil is provided for clinic.

The invention discloses a preparation method of amoxicillin sodium and clavulanate potassium for injection, belongs to the technical field of pharmaceutical preparations, and aims to solve the problems that related substances are easily generated in the production and storage of compound antibiotics, and the medication safety and the batch stability are influenced. According to the preparation, amoxicillin sodium and potassium clavulanate are used as main drugs, a specific antioxidant is compounded to inhibit potassium clavulanate oxidation and amoxicillin hydrolysis respectively, and a filling agent and a flow aid are used as auxiliary materials. During preparation, a premix is prepared through multi-step mixing, after wet granulation, segmented temperature control drying is adopted, temperature and vacuum degree are adjusted in a gradient mode, and nitrogen is filled for protection in the whole filling and capping process. According to the scheme, an oxidation and hydrolysis dual-degradation path is covered through antioxidant compounding, the dehydration efficiency and the drug stability are balanced through segmented drying, related substances can be reduced, the batch consistency is improved, the medication safety is guaranteed, and storage and transportation are convenient.

The application relates to the technical field of pharmaceutical preparations, in particular to a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof; a pharmaceutical composition comprises a co-micronization compound, the co-micronization compound comprises loratadine and a co-micronization carrier; the application discloses a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof, the dissolution rate and stability of the loratadine are improved by adopting the co-micronization technology and a new type of excipient combination; meanwhile, the prepared loratadine immediate-release tablet also has good in-vitro dissolution performance; the loratadine immediate-release tablet prepared by the application reduces impurity growth in the production and storage processes and obviously improves the stability of the drug; the loratadine immediate-release tablet disclosed by the application does not contain lactose in the prescription, so that the side reaction of lactose intolerance can be effectively avoided.

The invention relates to the technical field of biological medicine, in particular to a pharmaceutical preparation of quinazoline compounds and a preparation method and application of the pharmaceutical preparation. Compared with the prior art, the pharmaceutical preparation of the quinazoline compound has the advantages that the quality uniformity and the release controllability of the medicine can be guaranteed, the bioavailability and the medicine effect are improved, the medicine stability is improved, and the toxic and side effects are reduced. The pharmaceutical preparation of the quinazoline compound provided by the invention is expected to provide a new strategy for treatment of cancers, especially non-small cell lung cancer.